At a glance
Summary
IQVIA’s weekly setup is constructive but no longer early. The stock added 0.7% in the latest completed week, has gained 11.4% over four weeks and 42.7% over 12 weeks, putting it in the upper end of its 52-week range. Sharemaestro’s Trend backdrop remains active, with positive activity pressure and relative strength, but volume is running below average and next-week expectancy is negative at 43.88%.
- IQV closed at $261.75, 96.8% through its 52-week range and only 1.3% below the $265.25 high.
- The stock is 38.1% above its weekly Trend Line of $189.60 and 28.3% above Sharemaestro Fair Value of $203.96.
- The Trend backdrop is active for a fourth week, with activity pressure positive at 1.42 and relative strength at 18.20, but there is no fresh buy signal.
- Latest volume was 6.4M shares, below the 13-week average of 7.1M and the 52-week average of 7.9M.
- IQV outperformed a negative Healthcare week and a flat Diagnostics & Research group, although its industry four-week return trails the group average.
Company analysis
The move in context
Price action puts IQVIA near its high, but valuation has moved ahead
IQVIA Holdings, a $42.8B Healthcare name in Diagnostics & Research, closed the week of 28 August at $261.75, up 0.7%. The move was modest on its own, but it comes after a sharp recovery: 11.4% over four weeks, 42.7% over 12 weeks and 46.4% over 26 weeks. The stock now sits 96.8% through its 52-week range, with the latest close only 1.3% below the $265.25 high.
The strength has created a stretched price profile. IQV trades 38.1% above its weekly Trend Line at $189.60 and 28.3% above Sharemaestro Fair Value at $203.96. That premium reflects sustained demand, but it also means the next phase needs evidence beyond price alone, especially after such a large quarterly move.
Sector and industry context remains supportive, with some peer divergence
Healthcare had a weak latest week, with the US sector average down 1.49%, while IQV’s 0.7% gain ranked 15th out of 100 sector names. Over 12 weeks, IQV ranked 8th in the sector, helped by its 42.7% return versus the sector’s 17.0% average. Sector breadth is still constructive, with 65.0% of names showing active weekly trend signals, 77.0% showing positive activity pressure and 55.0% showing positive relative strength.
Within US Diagnostics & Research, the backdrop is even broader but more competitive. The group’s latest weekly average was slightly negative at -0.10%, while its four-week and 12-week averages were 15.4% and 30.0%. IQV ranked 12th of 44 for the week and 13th over 12 weeks, but only 24th over four weeks as faster movers such as Veeva, Charles River and several smaller diagnostics names have produced stronger short-term rebounds.
Signal state is constructive, while participation is the weak link
Sharemaestro’s setup signature is a Balanced read, with a composite score of 60. The Trend backdrop is active and has been active for four weeks, while the stock has logged active trend conditions in 27 of the past 52 weeks. Activity pressure is positive at 1.42 and the relative strength reading is 18.20, keeping the internal tone constructive.
The caveat is confirmation. The latest week’s 6.4M shares were only 0.9x the 13-week average and 0.8x the 52-week average. Earlier advances had clearer participation, including 12.5M shares during the 13.0% week ended 31 July and 9.0M shares during the 13.9% week ended 26 June. The current near-high push is therefore less forcefully confirmed by volume than the strongest legs of the rebound.
Risk profile: strong average gains, but reversal risk has risen
Weekly volatility is steady rather than extreme, with 13-week volatility at 6.0% versus a 52-week base of 6.2%. The distribution is mixed: 23 positive weeks and 28 negative weeks over the past year, although average winning weeks have been larger at 5.9% than average losing weeks at -3.4%. The best recent week was +13.9% in late June, while the worst was -8.0% in late April.
The watch-next issue is whether IQV can convert proximity to its high into a confirmed continuation move. A sustained hold above the current high area would support the active trend, while fading activity pressure, another low-volume gain or a break back toward the prior consolidation zone would raise the risk of exhaustion. Sharemaestro’s next-week expectancy is negative at 43.88%, and the data packet flags six recent reversal markers, so the near-term setup deserves closer monitoring despite the constructive trend state.
Peer comparison
How the wider group is behaving
Breadth shows how much of the sector or industry is participating. A company move is more convincing when its peers are improving too.
US Healthcare
100 tracked companiesAbove Trend Line65.0%
Positive Relative Strength55.0%
US Diagnostics & Research
44 tracked companiesAbove Trend Line75.0%
Positive Relative Strength59.1%
Balanced view
What supports the case, and what could weaken it
What is working
- The trend backdrop is active with a 4-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Activity pressure is constructive, supporting the smart-money activity read.
What needs caution
- Next-week expectancy is negative at 43.88% based on similar historical setup states.
- 6 reversal markers appear in the recent smart-money tape.
Research note
This article is for educational market research only and is not financial, investment, trading, tax, or legal advice. Sharemaestro does not make buy, sell, or hold recommendations.
Source and attribution
Source: Sharemaestro. Canonical article: https://sharemaestro.com/news/iqvia-42-7-quarter-volume-confirmation/.
Follow new Sharemaestro research through the RSS feed or JSON feed.